Manuel F Ugarte-Gil1,2, Guillermo J Pons-Estel3,4, Guillermina B Harvey5, Luis M Vilá6, Russell Griffin7, Graciela S Alarcón8,9. 1. Servicio de Reumatología, Hospital General Guillermo Almenara Irigoyen, EsSalud, Lima, Perú, United States. 2. Universidad Científica del Sur, Lima, Perú, United States. 3. Departamento de Medicina Interna, Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina. 4. Servicio de Reumatología, Hospital Provincial de Rosario, Rosario, Argentina. 5. Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina. 6. Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, Puerto Rico. 7. Department of Epidemiology, School of Public Health, The University of Alabama at Birmingham, Birmingham, Alabama, US, United States. 8. Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, US, United States. 9. Department of Medicine, School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Perú, United States.
Abstract
OBJECTIVE: To evaluate the performance of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria for Systemic Lupus Erythematosus (SLE) in terms of earlier SLE classification in comparison to the ACR or the Systemic Lupus International Collaborating Clinics (SLICC) criteria. MATERIALS AND METHODS: Patients from a multiethnic, multicenter cohort, the LUMINA cohort, where SLE was defined using the 1982/1997 ACR criteria were included. Demographic, clinical, and immunologic criteria were compared among the 2019 EULAR/ACR and the 1982/1997 ACR and the 2012 SLICC timing categories. RESULTS: The 2019 EULAR/ACR criteria allowed an earlier SLE classification in 13.3% (mean 0.66 years) and 15.3% (mean 0.63 years) than the 1982/1997 ACR and the 2012 SLICC criteria, respectively. Patients accruing the 2019 EULAR/ACR later than the 1982/1997 ACR criteria had a lower disease activity, were less likely to have positivity to anti-dsDNA and anti-Sm as well as lupus nephritis type II or V; they were more likely to have mucocutaneous manifestations, serositis, leukopenia and antiphospholipid antibodies positivity. These differences were less pronounced when compared to the 2012 SLICC criteria CONCLUSIONS: The 2019 EULAR/ACR criteria classified SLE patients earlier than with the two other criteria sets in real-life clinical practice scenarios in a relatively small proportion of the patients. However, these criteria could classify earlier a subset of patients with a more severe disease. This article is protected by copyright. All rights reserved.
OBJECTIVE: To evaluate the performance of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria for Systemic Lupus Erythematosus (SLE) in terms of earlier SLE classification in comparison to the ACR or the Systemic Lupus International Collaborating Clinics (SLICC) criteria. MATERIALS AND METHODS:Patients from a multiethnic, multicenter cohort, the LUMINA cohort, where SLE was defined using the 1982/1997 ACR criteria were included. Demographic, clinical, and immunologic criteria were compared among the 2019 EULAR/ACR and the 1982/1997 ACR and the 2012 SLICC timing categories. RESULTS: The 2019 EULAR/ACR criteria allowed an earlier SLE classification in 13.3% (mean 0.66 years) and 15.3% (mean 0.63 years) than the 1982/1997 ACR and the 2012 SLICC criteria, respectively. Patients accruing the 2019 EULAR/ACR later than the 1982/1997 ACR criteria had a lower disease activity, were less likely to have positivity to anti-dsDNA and anti-Sm as well as lupus nephritis type II or V; they were more likely to have mucocutaneous manifestations, serositis, leukopenia and antiphospholipid antibodies positivity. These differences were less pronounced when compared to the 2012 SLICC criteria CONCLUSIONS: The 2019 EULAR/ACR criteria classified SLEpatients earlier than with the two other criteria sets in real-life clinical practice scenarios in a relatively small proportion of the patients. However, these criteria could classify earlier a subset of patients with a more severe disease. This article is protected by copyright. All rights reserved.
Authors: Martin Aringer; Marta E Alarcón-Riquelme; Megan Clowse; Guillermo J Pons-Estel; Edward M Vital; Maria Dall'Era Journal: Ther Adv Musculoskelet Dis Date: 2022-03-30 Impact factor: 5.346